Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Townsend RR, et al. Renal denervation for treating hypertension: current scientific and clinical evidence. JACC Cardiovasc Inter. 2019;12:1095–105.
Katsurada K, Shinohara K, Aoki J, Nanto S, Kario K. Renal denervation: basic and clinical evidence. Hypertens Res. 2022;45:198–209.
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874–2071.
Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, et al. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA. 2023;329:651–61.
Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444–51.
Kario K, Böhm M, Mahfoud F, Townsend RR, Weber MA, Patel M, et al. Twenty-four-hour ambulatory blood pressure reduction patterns after renal denervation in the SPYRAL HTN-OFF MED Trial. Circulation. 2018;138:1602–4.
Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476–86.
Kandzari DE, Townsend RR, Kario K, Mahfoud F, Weber MA, Schmieder RE, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol. 2023;82:1809–23.
Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 2022;45:221–31.
Kario K, Kai H, Nanto S, Yokoi H. Anti-hypertensive medication adherence in the REQUIRE trial: post-hoc exploratory evaluation. Hypertens Res. 2023;46:2044–47.
Townsend RR, Ferdinand KC, Kandzari DE, Kario K, Mahfoud F, Weber MA, et al. Impact of antihypertensive medication changes after renal denervation among different patient groups: SPYRAL HTN-ON MED. Hypertension. 2024;81:1095–105.
Ogoyama Y, Abe M, Okamura K, Tada K, Katsurada K, Shibata S, et al. Effects of renal denervation on blood pressure in patients with hypertension: a latest systematic review and meta-analysis of randomized sham-controlled trials. Hypertens Res. 2024. https://doi.org/10.1038/s41440-024-01739-y
Katurada K, Kario K. Indications for renal denervation in the treatment of hypertension. Hypertens Res. 2024, https://doi.org/10.1038/s41440-024-01823-3.
Ogoyama Y, Kario K. Aspects of renal function and renal artery anatomy as indications for renal denervation. Hypertens Res. 2024, https://doi.org/10.1038/s41440-024-01860-y.
Kusayama T, Nagamori Y, Takeuchi K, Nakagawa Y, Takamura M. Renal autonomic dynamics in hypertension: how can we evaluate sympathetic activity for renal denervation? Hypertens Res. 2024, https://doi.org/10.1038/s41440-024-01816-2.
Katusrada K, Kario K. Effects of renal denervation on the incidence and severity of cardiovascular diseases. Hypertens Res. 2024, https://doi.org/10.1038/s41440-024-01858-6.
Yamazaki D, Konishi Y, Kitada K. Effects of renal denervation on the kidney: albuminuria, proteinuria, and renal function. Hypertens Res. 2024. https://doi.org/10.1038/s41440-024-01709-4
Shinohara K. Renal denervation for hypertensive heart disease and atrial fibrillation. Hypertens Res. 2024. https://doi.org/10.1038/s41440-024-01755-y
Ogoyama Y, Kario K. Differences in the effectiveness and safety of different renal denervation devices. Hypertens Res. 2024; https://doi.org/10.1038/s41440-024-01801-9
Okamura K, Shimada H, Imazato K, Sako H, Udo A, Taniguchi K, et al. Impact of renal denervation on quality of life (How does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?) Hypertens Res. 2024. https://doi.org/10.1038/s41440-024-01679-7
Kario K. What are the ideal metrics for assessing the quality of long-term stabilized “perfect” 24-hour BP control after renal denervation? Hypertens Res. 2024, https://doi.org/10.1038/s41440-024-01859-5.
Kario K, Kai H, Rakugi H, Hoshide S, Node K, Maekawa Y, et al. Consensus statement on renal denervation by the Joint Committee of the Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese CIrculation Society (JCS). Hypertens Res. 2024. https://doi.org/10.1038/s41440-024-01700-z